Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for misrepresentation and failure to disclose critical information regarding its drug candidate for Huntington's Disease, potentially affecting investors who purchased shares during the specified period [1][5]. Group 1: Lawsuit Announcement - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1]. - Investors who purchased shares during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Process and Participation - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by April 13, 2026, to represent the class in the litigation [1][3]. Group 3: Details of the Case - The lawsuit alleges that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [5]. - The claims suggest that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the truth was revealed [5]. Group 4: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4].

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. concerning allegations of securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves claims that uniQure and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until April 13, 2026, to request to be appointed as Lead Plaintiff if they purchased or acquired uniQure securities during the Class Period [2]. Group 2: Company Developments - On November 3, 2025, uniQure announced feedback from the U.S. FDA regarding its investigational gene therapy AMT-130 for Huntington's disease, indicating a shift in the FDA's stance on the adequacy of data from Phase I/II studies for a Biologics License Application (BLA) submission [4]. - Following this announcement, uniQure's stock price dropped by $33.40 per share, or 49.34%, closing at $34.29 per share on the same day [4].

ATLANTA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding uniQure’s business, operations, and prospects, including allegations that: (1) the design of uniQure’s Pivotal Study—including comparison of the Pivotal Study results to the ENROLL-HD external historical data set—was no ...

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired shares of uniQure N.V. between September 24, 2025, and October 31, 2025, due to allegations of misleading information regarding the FDA approval process for its drug candidate AMT-130 [1][2]. Group 1: Allegations and Impact - The lawsuit alleges that uniQure misled investors by failing to disclose that the design of its pivotal study was not fully approved by the FDA and that the company downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline for additional studies [2]. - On November 3, 2025, uniQure announced that the FDA no longer agreed that the data from its Phase I/II studies would be adequate for BLA submission, leading to a significant drop in share price from $67.69 to $34.29, a decline of over 49% [3]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers by April 13, 2026, and participation in the case is not required to be eligible for recovery [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. during the specified Class Period, indicating potential misrepresentation by the company regarding its drug candidate and regulatory approvals [1][5]. Group 1: Class Action Details - The class action lawsuit is for investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. Group 2: Allegations Against uniQure - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [5]. - It is alleged that the company's statements regarding its business operations and prospects lacked a reasonable basis, leading to investor damages when the true information became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

NEW YORK, Feb. 16, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 13, 2026. SO WHAT: If you purchased uniQure ordinary shares during the Class Period you may ...

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. on behalf of investors who purchased shares during a specified class period, alleging that the company made materially false and misleading statements regarding its drug candidate AMT-130 and its regulatory prospects with the FDA [1][11]. Company Overview - uniQure N.V. is a biotechnology company focused on developing gene therapies for rare diseases, including Huntington's disease (HD) [3]. - The company's leading drug candidate, AMT-130, aims to slow the progression of HD, a fatal inherited disorder with no existing cure [4]. Clinical Trials and FDA Interaction - uniQure completed patient enrollment for two ongoing Phase I/II clinical trials for AMT-130, known as the Pivotal Study, in March 2022 [4]. - The FDA had previously agreed that the Pivotal Study would not include a placebo comparator, allowing results to be compared to an external historical dataset, ENROLL-HD, for potential BLA submission [5]. Investor Communication and Stock Performance - On September 24, 2025, uniQure announced topline results from the Pivotal Study, leading to a significant increase in share price from $13.66 to $47.50, a nearly 250% rise [7][8]. - By October 29, 2025, shares were trading above $70.00, and the company raised approximately $345 million through a public offering shortly after the positive study results [9]. Allegations of Misrepresentation - The lawsuit alleges that uniQure misrepresented the FDA's approval of the Pivotal Study design and downplayed the likelihood of delays in the BLA timeline, leading to inflated stock prices based on misleading information [11]. - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the study data was adequate for BLA submission, resulting in a stock price drop of over 49% [10]. Legal Process for Investors - Investors who acquired uniQure shares during the class period may seek to be appointed as lead plaintiffs by April 13, 2026, to represent the class in the lawsuit [2][12].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. during the specified Class Period, indicating potential misrepresentation by the company regarding its drug candidate and regulatory approvals [1][5]. Group 1: Class Action Details - The class action lawsuit is for investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. Group 2: Allegations Against uniQure - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [5]. - It is alleged that the company's statements regarding its business operations and prospects lacked a reasonable basis, leading to investor damages when the true information became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against uniQure N.V. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by April 13, 2026 [4]. Group 1: Allegations Against uniQure - The complaint alleges that uniQure and its executives made false and misleading statements regarding the FDA approval of the design of the Pivotal Study and downplayed the likelihood of delays in the BLA timeline [6]. - It is claimed that the results from the Pivotal Study were not fully approved by the FDA, and the company would need to conduct additional studies to support its BLA submission [6]. - The disclosure on November 3, 2025, revealed that the FDA no longer agreed that the data from the Phase I/II AMT-130 studies would be adequate for BLA submission, contradicting previous statements about the path toward accelerated approval [7]. Group 2: Financial Impact - Following the disclosure, uniQure's share price fell by $33.40, a decline of over 49%, dropping from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [8]. Group 3: Legal Proceedings - The role of lead plaintiff in the class action is designated to the investor with the largest financial interest who is also typical of class members, with the option for any member to move the court to serve as lead plaintiff [9]. - Faruqi & Faruqi encourages anyone with information regarding uniQure's conduct to come forward, including whistleblowers and former employees [10].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. during the specified Class Period, indicating potential misrepresentation and lack of disclosure regarding the company's drug candidate and regulatory approvals [1][5]. Group 1: Class Action Details - The class action lawsuit is for investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm directly [3][6]. Group 2: Allegations Against uniQure - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [5]. - It is alleged that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the true information became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].